# A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC)

> **NCT05295927** · PHASE1 · TERMINATED · sponsor: **Janssen Research & Development, LLC** · enrollment: 3 (actual)

## Conditions studied

- Prostatic Neoplasms

## Interventions

- **DRUG:** EPI-7386
- **DRUG:** Abiraterone Acetate
- **DRUG:** Prednisone or Prednisolone
- **DRUG:** Apalutamide

## Key facts

- **NCT ID:** NCT05295927
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-03-23
- **Primary completion:** 2022-09-30
- **Final completion:** 2022-09-30
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Administrative Decision
- **Last updated:** 2025-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05295927

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05295927, "A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05295927. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*